|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, therapeutic angiogenesis using the VEGF gene has been used to treat ischemic heart disease since 1997.
|
12499610 |
2002 |
|
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AdGVVEGF121.10 (carrying the human vascular endothelial growth factor 121 cDNA) was administered (4 x 10(8) to 4 x 10(9.5) PU, single administration) directly to the myocardium of 11 individuals with ischemic heart disease.
|
10400771 |
1999 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of application of vascular endothelial growth factor (VEGF) GT strategies for therapeutic angiogenesis in critical limb and myocardial ischemia in pilot clinical trials was reviewed.
|
11773594 |
2001 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The central role of vascular endothelial growth factor (VEGF) in angiogenesis in health and disease makes it attractive both as a therapeutic target for anti-angiogenic drugs and as a pro-angiogenic cytokine for the treatment of ischaemic heart disease.
|
11166270 |
2001 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that controlled homogeneous VEGF delivery by FACS-purified transduced ASC is a promising strategy to achieve safe and functional angiogenesis in myocardial ischaemia.
|
29478261 |
2018 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia.
|
9860779 |
1999 |
|
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analyses indicated that the strongest associations with IHD and MI were due to the combined effect of the VEGFA-2578 A allele and smoking (OR 3.52 and 7.11, respectively), independent of risk factors such as age, sex, diabetes, C-reactive protein, hypercholesterolemia, and hypertension.
|
21362767 |
2011 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1.
|
18373738 |
2008 |
|
Myocardial Ischemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because hypoxia-inducible factor (HIF)-1alpha is a transcriptional activator of vascular endothelial growth factor (VEGF) and is critical for initiating angiogenic responses to hypoxia, we investigated the expression of HIF-1alpha and VEGF in specimens of human heart tissue to elucidate the molecular responses to myocardial ischemia in diabetic patients during unstable angina.
|
15331549 |
2004 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mobilization of endothelial progenitor cells with cytokines potentiates VEGF-2 gene therapy for myocardial ischemia and enhances bone marrow cell incorporation into ischemic myocardium.
|
15337699 |
2004 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, our study provides proof of principle that nanoparticle-mediated delivery increases the angiogenic and therapeutic potency of VEGF for the treatment of ischemic heart disease.
|
29101176 |
2018 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
For that, mouse BM cells were transduced with lentiviral vectors coding for <i>VEGFA</i> or sphingosine kinase (<i>SPHK1)</i>, which catalyzes S1P production, and injected them intravenously 4 and 7 days after cardiac ischemia-reperfusion in mice.
|
30786776 |
2019 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, the efficacy of therapeutic angiogenesis using VEGF (vascular endothelial growth factor) gene transfer has been reported in human patients with critical limb ischemia and myocardial ischemia.
|
11426585 |
2000 |
|
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, VEGF rs699947 and rs2010963 polymorphisms may serve as genetic biomarkers of poor collateral circulation after myocardial ischemia.
|
30317903 |
2018 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, about 200 patients have been treated with intramyocardial VEGF gene therapy for peripheral occlusive artery disease or for myocardial ischemia.
|
12582471 |
2002 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor-A is widely used in clinical trials for the treatment of cardiac ischemia.
|
16990600 |
2007 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings show that dysregulated angiogenic precursors link coronary anomalies to ischemic heart disease.Though coronary arteries are crucial for heart function, the mechanisms guiding their formation are largely unknown.Here, Wang et al. identify a unique, endocardially-derived angiogenic precursor cell population for coronary artery formation in mice and show that a DLL4/NOTCH1/VEGFA/VEGFR2 signaling axis is key for coronary artery development.
|
28924218 |
2017 |